Protara Therapeutics Statistics
Total Valuation
TARA has a market cap or net worth of $129.42 million. The enterprise value is -$36.39 million.
Important Dates
The next estimated earnings date is Friday, May 9, 2025, before market open.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TARA has 36.77 million shares outstanding. The number of shares has increased by 81.73% in one year.
| Current Share Class | 36.77M |
| Shares Outstanding | 36.77M |
| Shares Change (YoY) | +81.73% |
| Shares Change (QoQ) | +18.37% |
| Owned by Insiders (%) | 2.75% |
| Owned by Institutions (%) | 71.22% |
| Float | 30.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.71, with a Debt / Equity ratio of 0.03.
| Current Ratio | 15.71 |
| Quick Ratio | 15.54 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.88% and return on invested capital (ROIC) is -25.04%.
| Return on Equity (ROE) | -37.88% |
| Return on Assets (ROA) | -23.59% |
| Return on Invested Capital (ROIC) | -25.04% |
| Return on Capital Employed (ROCE) | -28.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.35M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.34% in the last 52 weeks. The beta is 1.59, so TARA's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +20.34% |
| 50-Day Moving Average | 4.04 |
| 200-Day Moving Average | 3.34 |
| Relative Strength Index (RSI) | 39.78 |
| Average Volume (20 Days) | 502,725 |
Short Selling Information
The latest short interest is 2.03 million, so 5.52% of the outstanding shares have been sold short.
| Short Interest | 2.03M |
| Short Previous Month | 2.08M |
| Short % of Shares Out | 5.52% |
| Short % of Float | 6.74% |
| Short Ratio (days to cover) | 7.82 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -49.15M |
| Pretax Income | -40.69M |
| Net Income | -44.60M |
| EBITDA | -48.82M |
| EBIT | -49.15M |
| Earnings Per Share (EPS) | -$2.17 |
Full Income StatementBalance Sheet
The company has $170.29 million in cash and $4.48 million in debt, giving a net cash position of $165.81 million or $4.51 per share.
| Cash & Cash Equivalents | 170.29M |
| Total Debt | 4.48M |
| Net Cash | 165.81M |
| Net Cash Per Share | $4.51 |
| Equity (Book Value) | 167.13M |
| Book Value Per Share | 4.77 |
| Working Capital | 161.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$35.81 million and capital expenditures -$63,000, giving a free cash flow of -$35.87 million.
| Operating Cash Flow | -35.81M |
| Capital Expenditures | -63,000 |
| Free Cash Flow | -35.87M |
| FCF Per Share | -$0.98 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |